Bellon Steven F. 4
4 · Foghorn Therapeutics Inc. · Filed Jan 30, 2023
Insider Transaction Report
Form 4
Bellon Steven F.
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2023-01-26+100,000→ 100,000 totalExercise: $8.38Exp: 2033-01-25→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.